Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.26 | N/A | +9.28% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.26 | N/A | +9.28% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding their product performance. They emphasized the importance of their pipeline but did not provide specific guidance.
Management highlighted the strong performance in key therapeutic areas.
They expressed confidence in the ongoing pipeline development.
Bristol Myers Squibb's earnings report showed a solid EPS beat, which contributed to a 3.3% increase in stock price. The positive surprise in EPS indicates stronger-than-expected profitability, although the lack of revenue data leaves some uncertainty. Investors may be encouraged by management's confidence in their product pipeline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Feb 2, 2026